CoChat

Comparative Efficacy and Safety of OADs in Management of GDM: Network Meta-analysis of Randomized Controlled Trials

Jiang, Yun-Fa, Chen, Xue-Yan, Ding, Tao, Wang, Xiao-Feng, Zhu, Zhong-Ning, Su, Su-Wen · 2015 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: We conducted a network meta-analysis to evaluate the efficacy and safety of oral antidiabetic drugs (OADs) for gestational diabetes. DATA SOURCES: We searched PubMed, the Cochrane Library, ClinicalTrials.gov, and related reviews from inception to October 2014. STUDY SELECTION: We included randomized clinical trials comparing efficacy and safety between different OADs or OADs vs insulin in patients with gestational diabetes. DATA SYNTHESIS: We included 18 randomized clinical trials. Traditional and network meta-analyses were performed to compare different OADs or OADs vs insulin. Traditional meta-analyses confirmed that there was no significant difference in maternal fasting blood glucose or glycated hemoglobin levels in patients treated with insulin, metformin, and glyburide. Compared to insulin, metformin was associated with lower maternal weight gain (weighted mean difference [WMD], -1.49 kg; 95% confidence interval [CI], -2.26 to -0.31), shorter gestational age (WMD, -0.16 wk; 95% CI, -0.30 to -0.03), and increased incidence of premature birth (odds ratio [OR], 1.63; 95% CI, 1.07 to 2.48). Compared to insulin, glyburide was associated with higher neonatal birth weight (WMD, 130.68 g; 95% CI, 55.98 to 205.38), increased incidence of neonatal hypoglycemia (OR, 2.64; 95% CI, 1.59 to 4.38), and increased incidence of macrosomia (OR, 3.09; 95% CI, 1.59 to 6.04). Network meta-analysis revealed that glyburide was associated with higher maternal weight gain, higher neonatal birth weight, increased incidence of neonatal hypoglycemia, and increased incidence of macrosomia than was metformin. CONCLUSION: Both metformin and glyburide are suitable for use in the management of gestational diabetes because of good glycemic control. However, glyburide treatment is associated with increased risk of neonatal hypoglycemia, high maternal weight gain, high neonatal birth weight, and macrosomia.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2014-4403

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 35 references

Cited by

Items 101–131 of 131

Metadata

Authors
Jiang, Y.-F., Chen, X.-Y., Ding, T., Wang, X.-F., Zhu, Z.-N., & Su, S.-W.
Affiliations
  • Hebei University of Chinese Medicine (CN)
  • Hebei Medical University (CN)
Corresponding author
Zhu, Zhong-Ning
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2015-05
Volume
100
Issue
5
Pages
2071-2080
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2129155490
Cited by
124
References
35
Citations by year
2026: 2 · 2025: 7 · 2024: 3 · 2023: 8 · 2022: 9 · 2021: 40 · 2020: 12 · 2019: 7 · 2018: 15 · 2017: 15 · 2016: 3 · 2015: 2
FWCI
1.72
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Natural Science Foundation of Hebei Province
  • Department of Health of Hebei Province
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
gestational diabetes mellitus, oral antidiabetic drugs, metformin, glibenclamide, insulin therapy, neonatal hypoglycemia, macrosomia, birth weight, gestational weight gain, glycemic control, HbA1c, preterm birth, gestational age, drug safety comparison, drug efficacy comparison, network meta-analysis of randomized controlled trials
MeSH terms
Administration, Oral, Blood Glucose, Female, Glyburide, Humans, Hypoglycemic Agents, Insulin, Metformin, Pregnancy, Pregnancy Outcome, Randomized Controlled Trials as Topic, Diabetes, Gestational, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.